UNSPSC 51432111: Guanethidine sulfate

This classification denotes an antihypertensive agent with the molecular formula 2C10H22N4.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8AQ60474G9, chemically known as 2-(1-n,n-heptamethyleneimino)ethylguanidine but more generally known as guanethidine sulfate, which bears US NIH Compound Identifier 3518. European Medicines Agency schedules Guanethidine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02426MIG.

Most nations, for tariff and trade purposes, schedule guanethidine sulfate under HS 29339990 and SITC 51577. As of Q4 2014, GUANETHIDINE SULFATE remains US FDA's Preferred Term for this commodity. Guanethidine sulfate bears US NLM identifiers UMLS ID C0700538 and NCI Concept Code C80000. SMILES: C1CCCN(CCC1)CCNC(=N)N.C1CCCN(CCC1)CCNC(=N)N.OS(=O)(=O)O.

UNSPSC 51432111 Guanethidine sulfate is a Commodity code covering a single pharmaceutical product line — specifically the antihypertensive agent guanethidine sulfate in injectable form. State and local governments procure this medication primarily through emergency medical services (EMS) and fire-rescue agencies that stock Advanced Life Support (ALS) medications for field deployment, alongside state health agencies and cooperative purchasing groups that aggregate pharmaceutical procurement across multiple jurisdictions and healthcare facilities. The work being solicited under this code reflects spot purchases of specific medication units with firm expiration-date requirements (typically nine months or more from acceptance), delivery within tight timeframes (ten calendar days), and comprehensive warranty and replacement obligations that shift expired-inventory risk to the vendor.

Recent activity clusters in Florida and a multi-state cooperative purchasing mechanism. The City of Tampa's Purchasing Department solicited 26P00188 (Advanced Life Support Medications) via IFB on April 24, 2026, with response due April 8, 2026—a spot buy of four ALS medication line items including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem totaling an estimated $40,000 for one-year term with two optional renewals and unilateral 30-day extensions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) due March 26, 2026, establishing framework contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with effective date July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as exploratory market research into direct-to-manufacturer prescription programs rather than a committed procurement. Guanethidine sulfate does not appear in the named line items of recent solicitations; the code shows limited direct recent activity at the Commodity level.